Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most common liver disease globally, linked to obesity and diabetes. Studies are exploring the use of GLP-1 RAs to treat MASLD by aiding in weight loss and controlling diabetes. GLP-1 RAs have shown promise in resolving MASH and liver fibrosis as well as reducing liver fat content. Dual and triple-action agents like tirzepatide and survodutide have also shown positive results in resolving MASH without worsening fibrosis. However, challenges with side effects and access remain. Research in this area is rapidly evolving, with newer agents and treatments being developed to address MASLD.
Source link
Can We Repurpose Obesity Drugs to Reverse Liver Disease?
